AMRN vs. ADCT, ANRO, HROW, CRBP, ERAS, MREO, RANI, MRSN, TERN, and ANNX
Should you be buying Amarin stock or one of its competitors? The main competitors of Amarin include ADC Therapeutics (ADCT), Alto Neuroscience (ANRO), Harrow (HROW), Corbus Pharmaceuticals (CRBP), Erasca (ERAS), Mereo BioPharma Group (MREO), Rani Therapeutics (RANI), Mersana Therapeutics (MRSN), Terns Pharmaceuticals (TERN), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
ADC Therapeutics (NYSE:ADCT) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Amarin has a net margin of -18.96% compared to Amarin's net margin of -330.17%. ADC Therapeutics' return on equity of -9.48% beat Amarin's return on equity.
Amarin has higher revenue and earnings than ADC Therapeutics. Amarin is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
ADC Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Amarin has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 35.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Amarin received 791 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 64.56% of users gave ADC Therapeutics an outperform vote.
ADC Therapeutics presently has a consensus price target of $7.25, indicating a potential upside of 77.26%. Amarin has a consensus price target of $1.08, indicating a potential upside of 18.73%. Given Amarin's stronger consensus rating and higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Amarin.
In the previous week, ADC Therapeutics had 2 more articles in the media than Amarin. MarketBeat recorded 3 mentions for ADC Therapeutics and 1 mentions for Amarin. ADC Therapeutics' average media sentiment score of 1.37 beat Amarin's score of 0.43 indicating that Amarin is being referred to more favorably in the news media.
Summary
Amarin beats ADC Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Amarin News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
